Ajay S. Behl, PhD, Janssen Pharmaceuticals, discusses a study examining the central nervous system (CNS) and dose-reduction events in patients with metastatic castration-resistant prostate cancer (mCRPC) following treatment with abiraterone acetate (Zytiga) plus prednisone.

These events were observed in comparison with patients who were treated with enzalutamide (Xtandi), Behl explains. This study is part of a larger investigation that is seeking to understand the differences between oral therapies used to treat mCRPC, including abiraterone and enzalutamide.

Results showed that patients who were treated with enzalutamide experienced more CNS events and fatigue compared with patients in the abiraterone and prednisone arm, Behl says.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Prostate Cancer

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

ASCO Annual Meeting

Conference

Ajay S. Behl, PhD, Janssen Pharmaceuticals, discusses a study examining the central nervous system (CNS) and dose-reduction events in patients with prostate cancer following treatment with abiraterone acetate (Zytiga) plus prednisone.

CNS and Dose-Reduction Events After Abiraterone/Prednisone in mCRPC